I TOLD YOU!!! Sarepta to $50 & Another BEAUTIFUL Long Biotech Stock | Celcuity | Martin Shkreli

About this Video

• Video Title: I TOLD YOU!!! Sarepta to $50 & Another BEAUTIFUL Long Biotech Stock | Celcuity | Martin Shkreli
• Channel: The Shkreli Pill
• Speaker(s): Martin Shkreli
• Duration: 00:23:26

Introduction

This video is a stock market commentary by Martin Shkreli focusing on Sarepta Therapeutics (SRPT) and Celcuity (CELC). Shkreli discusses the FDA's decision to allow Sarepta to resume shipments, analyzes its potential price increase, and evaluates Celcuity's prospects based on successful clinical trial results. He also touches upon broader market trends in AI and biotech.

Key Takeaways

• Sarepta Therapeutics (SRPT): The FDA lifted its pause on Sarepta's shipments, leading Shkreli to predict a price increase to $50 or higher. He suggests a buy at $20 and a potential sell point around $30.
• Celcuity (CELC): Celcuity's successful Gedatolisib trial is highlighted as a positive indicator for the company. Shkreli considers it a potential buy, though further analysis is warranted.
• AI Market: The video comments on significant activity in the AI market, particularly the Anthropic deal and its implications for Nvidia's stock price, suggesting potential growth to $200.
• Market Outlook: Shkreli expresses a generally positive outlook for the market, noting overextension but predicting continued growth until a market correction.
• Biotech Investment Strategy: The video emphasizes the potential for profitability in biotech, even with imperfect drugs, as they pave the way for future, more effective treatments.